| Literature DB >> 31609983 |
Thi T Hang Pham1, Thuy X Le2, Dong T Nguyen2, Chau M Luu2, Bac D Truong2, Phu D Tran2, Mehlika Toy1, Selen Bozkurt3, Samuel So1.
Abstract
BACKGROUND AND AIM: Vietnam's burden of liver cancer is largely due to its high prevalence of chronic hepatitis B virus (HBV) infection. This study aimed to examine healthcare workers' (HCWs) knowledge, attitude and practices regarding HBV prevention and management.Entities:
Year: 2019 PMID: 31609983 PMCID: PMC6791544 DOI: 10.1371/journal.pone.0223733
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Distribution of demographic factors and HBV related experience (N = 314).
| N | % | |
|---|---|---|
| Under 25 years | 54 | 17.2 |
| 25–34 years | 152 | 48.4 |
| 35–45 years | 64 | 20.4 |
| Above 45 years | 44 | 14.0 |
| Male | 108 | 34.4 |
| Female | 206 | 65.6 |
| Physician | 99 | 31.5 |
| Physician assistant | 89 | 28.3 |
| Nurse | 50 | 15.9 |
| Midwife | 62 | 19.6 |
| Others (medical student and lab technician) | 14 | 4.4 |
| Internal medicine | 49 | 15.6 |
| Obstetric | 64 | 20.4 |
| Pediatric | 47 | 15.0 |
| General medicine | 64 | 20.4 |
| Other | 90 | 28.7 |
| Commune health center | 79 | 25.2 |
| District health hospital | 142 | 45.2 |
| Province level hospital | 93 | 29.6 |
| <5 years | 99 | 31.5 |
| 5–10 years | 112 | 35.7 |
| >10 years | 103 | 32.8 |
| Yes | 255 | 81.2 |
| No | 59 | 18.8 |
| Yes | 216 | 68.8 |
| No | 98 | 31.2 |
| Yes | 234 | 74.5 |
| No | 80 | 25 |
| Yes | 144 | 45.9 |
| No | 170 | 54.1 |
Distribution of correct responses to HBV risk, prevention, and management (N = 314).
| Questions | Correct answers | |
|---|---|---|
| N | % | |
| Q8. How many percent of Vietnam population has CHB? | 130 | 41.4 |
| Q9. How did most people who have CHB in Vietnam got infected | 124 | 39.5 |
| Q10. Which age group is most likely to develop CHB infection after the initial infection? | 77 | 24.5 |
| Q11. Consequences of CHB infection? | 234 | 74.6 |
| Q12. Hepatitis B can be transmitted through handshake | 279 | 88.9 |
| Q13. Hepatitis B can be transmitted through unprotected sex | 268 | 85.4 |
| Q14. Hepatitis B can be transmitted through blood transfusion | 279 | 88.9 |
| Q15. Hepatitis B can be transmitted through sneezing or coughing | 257 | 81.9 |
| Q16. Hepatitis B can be transmitted through from mother to her child at birth | 283 | 90.1 |
| Q17. Hepatitis B can be transmitted through from eating or sharing food/utensils with HBV infected patients | 219 | 69.8 |
| Q18. Clean and cook food thoroughly can prevent HBV transmission | 159 | 50.6 |
| Q19. Hepatitis B vaccination to persons with no immunity can prevent HBV transmission | 286 | 91.1 |
| Q20. Do not reuse or share needles/syringes can prevent HBV transmission | 289 | 92.0 |
| Q21. Avoid sharing food/utensils or eating with a person with CHB can prevent HBV transmission | 175 | 55.7 |
| Q22. Use a condom can prevent HBV transmission | 287 | 91.4 |
| Q23. Who should be vaccinated to prevent HBV infection? | 231 | 73.6 |
| Q24. When would you give a healthy and stable baby the first dose of the hepatitis B vaccine? | 281 | 89.5 |
| Q25. Do you think the hepatitis B vaccine is safe? | 192 | 61.2 |
| Q26. If a pregnant woman has CHB, what would you do to protect the newborn from becoming infected? | 233 | 74.2 |
| Q29. Wash hands with soap or disinfectant after each clinical procedure can prevent needle stick injury | 259 | 82.5 |
| Q30. Recap needle with two hands after use and discard immediately in a sharp-proof container can prevent needle stick injury | 159 | 50.6 |
| Q31. Do not recap needle and discard immediately in a sharp-proof container can prevent needle stick injury | 148 | 47.1 |
| Q37. Would pregnant women need HBV screening test even though they don’t have any hepatic symptoms? | 271 | 86.3 |
| Q38. Would people living with HIV need HBV screening test even though they don’t have any hepatic symptoms? | 255 | 81.2 |
| Q39. Would men who have sex with men (MSM) need HBV screening test even though they don’t have hepatic symptoms? | 256 | 81.5 |
| Q40. Would family member of CHB patients need HBV screening test even though they don’t have hepatic symptoms? | 284 | 90.5 |
| Q41. Which single test would you order to confirm a patient has CHB? | 278 | 88.5 |
| Q42. Which single test would you order to know if a patient has immunity to HBV? | 116 | 36.9 |
| Q47. Do all patients with CHB need to be regularly monitored and screened for liver cancer? | 43 | 13.7 |
| Q49. Would you order alpha-fetoprotein (AFP) to screen for liver cancer? | 175 | 55.7 |
| Q50. Would you order alanine transaminase (ALT) to screen for liver cancer? | 102 | 32.5 |
| Q51. Would you order (AST) to screen for liver cancer? | 101 | 32.2 |
| Q52. Would you order abdominal ultrasound to screen for liver cancer? | 88 | 28.0 |
| Q53. Would you order carcinoembryonic antigen (CEA) to screen for liver cancer? | 83 | 26.4 |
| Q54. Would you order alpha-fetoprotein (AFP) for regular monitoring of liver damage? | 81 | 25.8 |
| Q55. Would you order alanine transaminase (ALT) for regular monitoring of liver damage? | 147 | 46.8 |
| Q56. Would you order aspartate aminotransferase (AST) for regular monitoring of liver damage? | 63 | 20.1 |
| Q57. Would you order abdominal ultrasound for regular monitoring of liver damage? | 84 | 26.8 |
| Q44. What is the symptom most patients with CHB present? | 43 | 13.7 |
| Q45. Is there a cure for CHB? | 193 | 61.5 |
| Q46. Do you think that every patient with CHB need to receive antiviral treatment? | 64 | 20.4 |
| Q48. Without proper monitoring and treatment, what is the chance a patient would die of complications of CHB? | 69 | 22.0 |
Attitude and medical practice regarding HBV prevention (N = 314).
| N | % | |
|---|---|---|
| Yes, always available | 184 | 58.6 |
| Yes, but stock-out occurs | 62 | 19.7 |
| Not available | 46 | 14.7 |
| Don’t know | 22 | 7.0 |
| Always | 174 | 61.3 |
| Sometimes | 97 | 34.1 |
| Never | 13 | 4.6 |
| I am not involved in giving injection to patients | 30 | |
| I often recap needle with two hands after injection | 137 | 48.2 |
| I often recap needle with one hand after injection | 94 | 33.1 |
| I often don’t recap needle after injection | 53 | 18.7 |
| I am not involved in giving injection to patients | 30 | |
| Yes | 76 | 24.2 |
| No | 208 | 66.2 |
| I am not involved in giving injection to patients | 30 | 9.6 |
| Always | 259 | 82.5 |
| At some places | 45 | 14.3 |
| Not available | 10 | 3.2 |
| Yes | 85 | 27.0 |
| Somewhat concern | 47 | 15.0 |
| No | 182 | 58.0 |
| Yes | 70 | 22.3 |
| Somewhat concern | 58 | 18.5 |
| No | 186 | 59.2 |
| Yes | 65 | 20.7 |
| Somewhat concern | 69 | 22.0 |
| No | 180 | 57.3 |
Average and maximum score of different domains of HBV knowledge (N = 314).
| Average score ± SD | Median score (min-max) | Highest possible score | |
|---|---|---|---|
| HBV prevalence and risk | 1.8 ± 1.0 | 2 | 4 |
| HBV transmission route | 5.0 ± 1.3 | 5 (0–6) | 6 |
| HBV prevention measures | 3.8 ± 1.1 | 4 (0–5) | 5 |
| Hepatitis B immunization | 3.0 ± 1.0 | 3 (0–4) | 4 |
| Injection safety | 1.8 ± 0.7 | 2 (0–3) | 3 |
| Hepatitis B testing | 4.6 ± 1.2 | 5 (0–6) | 6 |
| CHB monitoring | 3.1 ± 2.2 | 3 (0–8) | 10 |
| CHB treatment | 1.4 ± 0.8 | 1 (0–4) | 4 |
| Total HBV knowledge score | 25 ± 4.5 | 25 (9–34) | 42 |
Analysis of factors associated with HBV total knowledge score (N = 314).
| Univariate linear regression analysis | Multivariate linear regression analysis | ||||||
|---|---|---|---|---|---|---|---|
| Variables | Coef. | t | P | Adjusted Coef. | 95% CI | P | |
| Under 25 years | Ref | - | - | Ref | - | - | |
| 25–34 years | 1.7 | 2.5 | 0.02 | 0.1 | -1.9 to 2.00 | 0.94 | |
| 35–45 years | 1.6 | 2.0 | 0.05 | -0.1 | -2.5 to 2.4 | 0.94 | |
| Above 45 years | 1.19 | 1.3 | 0.19 | -0.3 | -2.9 to 2.3 | 0.80 | |
| Ref | - | - | Ref | - | - | ||
| Female | -0.2 | -0.4 | 0.72 | ||||
| Physician | Ref | - | - | Ref | - | - | |
| Physician assistant | -2.6 | -4.1 | <0.001 | -2.5 | -3.8 to -1.1 | <0.001 | |
| Nurse | -4.4 | -3.6 | <0.001 | -4.6 | -7.5to -1.8 | 0.001 | |
| Midwife | -2.9 | -3.9 | <0.001 | -3.0 | -4.5 to -1.5 | <0.001 | |
| Others | -3.3 | -4.7 | <0.001 | -3.6 | -5.1 to -2.1 | <0.001 | |
| Internal medicine | Ref | - | - | Ref | - | - | |
| Obstetric | -0.9 | -1.0 | 0.31 | 0.2 | -1.5 to 2.0 | 0.78 | |
| Pediatric | -0.4 | -0.4 | 0.68 | -0.6 | -2.4 to 1.2 | 0.51 | |
| General medicine | -1.2 | -1.4 | 0.16 | -0.6 | -2.3 to 1.1 | 0.48 | |
| Others | -0.8 | -1.0 | 0.34 | -0.1 | -1.7 to 1.4 | 0.86 | |
| Commune health center | Ref | - | - | Ref | - | - | |
| District health hospital | 0.8 | 1.2 | 0.23 | 0.4 | -0.8 to 1.7 | 0.51 | |
| Province level hospital | -0.0 | -0.0 | 0.98 | 0.4 | -1.0 to 1.9 | 0.56 | |
| <5 years | Ref | - | - | Ref | - | - | |
| 5–10 years | 0.8 | 1.2 | 0.22 | 0.4 | -1.0 to 1.7 | 0.60 | |
| >10 years | 0.3 | 0.4 | 0.70 | -0.10 | -1.9 to 1.8 | 0.95 | |
| Yes | Ref | - | - | Ref | - | - | |
| No | -1.2 | -1.7 | 0.08 | -1.0 | -2.3 to 0.3 | 0.11 | |
| Yes | Ref | - | - | Ref | - | - | |
| No | -1.0 | -1.8 | 0.68 | ||||
| Yes | Ref | - | - | Ref | - | - | |
| No | -1.6 | -2.7 | 0.006 | -1.1 | -2.3 to 0.6 | 0.062 | |
| Yes | Ref | - | - | Ref | - | - | |
| No | -1.0 | -2.0 | 0.05 | -1.1 | -2.1 to -0.1 | 0.026 | |